- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05975554
The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution. (ELLIPSE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Up till now our Lab has looked at Tregs and immune cells in the blood. The question remains whether low dose IL-2 can have the desired effect on Tregs in atherosclerotic plaques where they could alter the pathophysiology and potentially clinical outcomes for patients.
Up until recently, the cellular composition and cell-specific expression patterns of human atherosclerotic plaques remained elusive. However, recent breakthroughs studies using scRNA-seq, CITE-seq, and single-cell ATAC-seq on human carotid plaques have offered important insight into plaque composition, cell heterogeneity, and cell-cell interactions giving new perspectives on mechanisms of disease. The next logical stage is to use this new insight and powerful biological tool to assist in drug development for patients.
Therefore, the aims of the study are:
- To assess if low dose IL-2, given systemically to patients at our proposed dose, can alter Tregs in atherosclerotic plaques (the disease tissue) to exhibit a proliferating, activated, and immunosuppressive phenotype
- To assess if modulating plaque Tregs can cause a shift in the plaque immune landscape to a less inflammatory phenotype
- To study the relationship between plaque and circulating immune cells after systemic immune modulation
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
- Addenbrookes Hospital
-
Contact:
- Tian Zhao, MBBS, PhD
- Phone Number: 01223768678
- Email: Txz20@cam.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Presence of carotid stenosis on either ultrasound or CT scan.
- Planned to undergo carotid endarterectomy.
Exclusion Criteria:
- Autoimmune disease
- Any regular immunosuppressive treatment [Inhaled or topical steroids are permissible]
- Modified Rankin Scale score of ≥4 at screening
- Known active hepatic disease or alanine aminotransferase (ALT) > 2xULN
- Severe chronic kidney disease (defined as eGFR < 30 ml/min/1.73m2)
- Allergy or intolerance to aldesleukin
- Signs or symptoms of active infection
- History of human immunodeficiency virus (HIV), hepatitis B or C
- Current malignancy requiring active treatment
- Vaccine within 4 weeks prior to screening or plans for vaccination during study period
- Women of child-bearing potential and pregnancy
- Women who are breast-feeding
- Clinically relevant medical or surgical conditions that, in the opinion of the
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose interleukin-2
Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC.
|
5 sequential days of treatment (1.5MIU/day subcutaneously)
Standard care for patients with carotid stenosis undergoing carotid endarterectomy
|
Active Comparator: Control
Standard of care treatment
|
Standard care for patients with carotid stenosis undergoing carotid endarterectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in gene expression in Tregs
Time Frame: Time of surgery
|
Comparing differential gene expression using scRNA-seq technologies, from isolated Tregs from carotid plaques from the two patient groups (IL-2 treatment and control).
Differential gene expression will be assessed using standard techniques (Z-Score)
|
Time of surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in gene expression in Teff cells.
Time Frame: Time of surgery
|
Comparing differential gene expression using scRNA-seq technologies, from isolated Teffs from carotid plaques from the two patient groups (IL-2 treatment and control).
Differential gene expression will be assessed using standard techniques (Z-Score)
|
Time of surgery
|
Immune cell gene signature, in plaque and blood.
Time Frame: Time of surgery
|
Difference in immune cell gene signature will be compared using scRNA-seq in both plaque and blood samples, and further compared between IL-2 and control groups.
Comparative analysis will be completed using gene set enrichment analysis (Enrichment Score).
|
Time of surgery
|
Difference in gene expression patterns in Treg & Teff cells.
Time Frame: Baseline and at time of surgery
|
Comparison between Treg and Teff cells collected at baseline and day of surgery will be compared between IL-2 and control groups.
Differential gene expression will be assessed using standard techniques (Z-Score)
|
Baseline and at time of surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Other immune cell and vascular smooth muscle cell gene expression
Time Frame: Time of surgery
|
As per primary outcome measure but in immune cells and vascular smooth muscle cells (excluding Treg & Teff cells).
Differential gene expression will be assessed using standard techniques (Z-Score)
|
Time of surgery
|
Ligand-receptor interactions.
Time Frame: Time of surgery
|
Differential regulation of ligand-receptor interactions between control and IL-2 treated cells will be identified by comparing single-cell/single-cell ligand-receptor interaction scores for the two groups.
This measure is descriptive in nature.
|
Time of surgery
|
T-Cell receptor profile
Time Frame: Time of surgery
|
Difference in TCR clonality in plaques between the two groups will be assessed from clonotypes based on identical V-J gene usage and identical CDR3 junctions.
|
Time of surgery
|
Inflammatory pathway activation.
Time Frame: Time of surgery
|
Activation of inflammatory pathways both at plaque and systemic level.
Assess for enrichment of genes involved in inflammatory pathways - enrichment score.
|
Time of surgery
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Pathological Conditions, Anatomical
- Carotid Stenosis
- Carotid Artery Diseases
- Atherosclerosis
- Plaque, Atherosclerotic
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Interleukin-2
Other Study ID Numbers
- A096090
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carotid Artery Plaque
-
University Hospital OstravaCharles University, Czech Republic; University Hospital Olomouc; University of... and other collaboratorsActive, not recruiting
-
Marc van SambeekEindhoven University of TechnologyUnknown
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingCarotid Artery Plaque | Carotid Stenosis | Carotid Artery Diseases | Carotid Atherosclerosis | Atheroma; Carotid ArteryFrance
-
Canadian Medical and Surgical Knowledge Translation...AmgenRecruitingCarotid Artery Stenosis | Asymptomatic Carotid Artery StenosisCanada
-
Xuanwu Hospital, BeijingRecruitingCarotid Artery Plaque | Carotid Artery Stenting | Carotid EndarterectomyChina
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCarotid Artery Plaque | Carotid Stenosis | Plaque, AtheroscleroticUnited States
-
Second Affiliated Hospital, School of Medicine,...RecruitingCarotid Artery Plaque | Plaque, Atherosclerotic | Immune Checkpoint Inhibitors | Programmed Cell Death Protein 1 Inhibitor | Intimal Medial Thickness of Internal Carotid ArteryChina
-
Arizona Heart InstituteVolcano CorporationCompletedCarotid Artery DiseaseUnited States
-
Heinrich-Heine University, DuesseldorfRecruitingCarotid Artery Plaque | Carotid Artery Diseases | Carotid Artery Stenosis Asymptomatic | Carotid Artery StenosisGermany
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI); Cedars-Sinai Medical Center and other collaboratorsRecruitingCarotid Atherosclerosis | Asymptomatic Carotid Artery Stenosis | Carotid Artery AtheromaUnited States
Clinical Trials on Interleukin-2 [IL-2]
-
University of Michigan Rogel Cancer CenterUniversity of MichiganTerminated
-
Iovance Biotherapeutics, Inc.RecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Loma Linda UniversityWithdrawnMelanoma | Metastatic Kidney CancerUnited States
-
Assistance Publique - Hôpitaux de ParisIltoo PharmaActive, not recruitingRecurrent MiscarriageFrance
-
Providence Health & ServicesPrometheus LaboratoriesActive, not recruitingMetastatic MelanomaUnited States
-
French National Agency for Research on AIDS and...Chiron CorporationCompleted
-
King's College LondonKing's College Hospital NHS TrustTerminatedLiver Diseases | TransplantationUnited Kingdom
-
VicalNational Cancer Institute (NCI); Jonsson Comprehensive Cancer CenterTerminatedProstate CancerUnited States
-
VicalNational Cancer Institute (NCI); Jonsson Comprehensive Cancer CenterTerminated
-
Brigham and Women's HospitalTerminatedAbdominal Wall Defect | Amputation, Traumatic | Amputation;Traumatic;Old | Face Injury | Face; DeformityUnited States